Home/Companies/Genmab A/S

Genmab A/S (GMAB.CO) : key figures and financial history

Historical revenue, net income, net margin and earnings per share of Genmab A/S, year by year from 2010 to 2025. Market data, amounts in US dollars.

Sector
Health
Country / place
🇩🇰 Europe
Market cap
31,26 billion $
Price at 13/11/2026
3 448,00 DKK

Year-by-year financial history

Revenue, net income, net margin, earnings per share (EPS) and revenue growth. Amounts in USD.

YearRevenueNet incomeNet marginBPARevenue growth
201085,83 M$-47,40 M$-55,2 %-0,47 $n/d
201151,75 M$-87,93 M$-169,9 %-1,96 $-39,7 %
201271,46 M$-71,83 M$-100,5 %-1,56 $+38,1 %
201397,84 M$16,57 M$16,9 %0,20 $+36,9 %
2014125,39 M$44,43 M$35,4 %0,79 $+28,2 %
2015167,07 M$112,58 M$67,4 %1,92 $+33,2 %
2016267,79 M$175,03 M$65,4 %2,92 $+60,3 %
2017348,78 M$162,72 M$46,6 %2,67 $+30,2 %
2018446,06 M$217,07 M$48,7 %3,54 $+27,9 %
2019791,22 M$319,38 M$40,4 %5,07 $+77,4 %
20201,49 billion $701,57 M$47,1 %10,76 $+88,4 %
20211,25 billion $436,01 M$34,9 %6,78 $-16,1 %
20222,15 billion $803,90 M$37,4 %12,29 $+72,1 %
20232,43 billion $641,70 M$26,4 %9,83 $+12,9 %
20243,17 billion $1,16 billion $36,4 %18,02 $+30,7 %
20253,86 billion $999,19 M$25,9 %16,08 $+21,6 %

Revenue and net income evolution

Graphical representation of annual amounts (in USD).

20102012201420162018202020222024
RevenueNet income

Current ratios

Valuation and profitability; price ratios calculated based on the price of 13/11/2026.

P/E
40,58
ROE
17,1 %
Debt / EPS
0,95
Methodology. The amounts (turnover, net income) are expressed in US dollars, converted at the 15/11/2026 exchange rate; the share price is displayed in its trading currency; ratios are currency-neutral. Revenue growth is calculated from one year to the next based on published real values. No value is estimated: a missing data point is noted as "n/d" or is not displayed. This information does not constitute investment advice. Share price and market capitalization as of 13/11/2026.